查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1830578

癌症診斷市場（按技術、癌症類型和最終用戶分類）—2025-2032 年全球預測

Cancer Diagnostics Market by Technology, Cancer Type, End User - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年癌症診斷市場規模將成長至 832.3 億美元，複合年成長率為 12.12%。

主要市場統計數據
基準年2024年 333.1億美元
預計2025年 373.2億美元
預測年份：2032年 832.3億美元
複合年成長率（%） 12.12%

由技術融合、護理途徑轉變和監管變化推動的不斷發展的癌症診斷格局的緊急而全面的方向

在技​​術融合、監管格局調整和臨床路徑轉變的推動下，癌症診斷領域正經歷快速發展。分子平台、高解析度成像和先進細胞分析技術的進步，正在提升臨床醫生和研究人員檢測、分型和監測癌症的能力，使其達到前所未有的精確度。同時，隨著診斷決策越來越貼近患者，多學科團隊需要整合組織病理學、基因組序列測定和影像學衍生生物標記的綜合資訊流，醫療保健服務模式也在改變。

在此背景下，市場參與企業面臨複雜的創新機會和營運挑戰。診斷開發者在檢測靈敏度和特異性、通量以及擁有成本方面展開競爭，而醫療保健系統則日益強調基於價值的結果和診斷效率。伴隨診斷和次世代定序儀流程的監管預期日趨成熟，支付方正在重新評估那些有望改善治療方案並降低下游成本的檢測的報銷途徑。因此，競爭格局將有利於那些能夠將科學嚴謹性與務實的部署策略相結合，並有效應對臨床工作流程和報銷現實情況的機構。

本執行摘要概述了改變癌症診斷領域最重要的趨勢，分析了政策和關稅可能帶來的衝擊，並提供了按技術、癌症類型和最終用戶細分的洞察，評估了區域動態，並為尋求提升競爭力的企業提供了戰略選擇。這份連貫的敘述為癌症診斷及相關服務的相關人員在製定公司策略、投資決策和產業計畫時提供了參考。

技術民主化、多模態資料整合和監管重組如何共同重新定義癌症診斷途徑和商業性要務

一系列相互關聯的變革正在改變腫瘤診斷領域，這些變革共同重新定義著臨床實踐和商業機會。科技的普及化是核心主題。隨著檢測工作流程的簡化、自動化技術的進步以及數位化介面對結果解讀的標準化，曾經專屬於專業參考實驗室的平台正在遷移到常規醫院實驗室和門診環境中。這種廣泛應用正在加速分子診斷和先進免疫檢測在社群中的應用，從而實現更早的檢測和更詳細的疾病分層。

同時，多模態資料流的整合正在重塑診斷結果。臨床醫生如今期望獲得將基因組學觀察與免疫組化模式、空間分析和橫斷面成像生物標記相結合的報告，從而創建更具可操作性的診斷敘述，用於精準治療選擇和縱向監測。這種轉變將有利於那些能夠提供可互操作系統和精選數據平台的公司，這些平台能夠促進病理學、放射學和分子診斷團隊之間的跨學科合作，並減少數據合成過程中的摩擦。

付款方和法規環境也在影響策略方向。付款方越來越重視臨床效用和真實世界結果，促使診斷開發商投資於實證項目和結果研究。監管機構正在調整框架，以適應新型檢測模式、伴隨診斷和分散式檢查，這加速了對強力的分析驗證和上市後監管的需求。最後，供應鏈彈性和成本壓力正在推動製造業重組和更具選擇性的採購，以及專注於確保關鍵試劑供應和儀器服務網路的垂直整合和策略聯盟。

總的來說，這些變革意味著單靠技術創新是不夠的；它需要可互通的解決方案、基於證據的採用策略和營運彈性，以實現具有臨床影響和商業性永續的診斷。

評估 2025 年美國關稅對供應鏈、採購成本和診斷技術策略部署的多方面影響

美國2025年宣布或實施的關稅變化將對腫瘤診斷領域的公司產生複雜的上下游影響。最直接的影響是，進口設備和試劑關稅的提高可能會增加成像設備、流式細胞儀和定序儀等高價值設備以及國內尚無成熟製造替代方案的專用耗材的到岸成本。這些成本壓力可能會擠壓依賴全球供應鏈的製造商的淨利率，並增加進口設備或依賴外國試劑的實驗室和醫療系統的採購成本和單次檢測成本。

關稅除了直接影響價格外，還可能引發整個價值鏈的策略性因應措施。製造商可能會加速生產在地化，將採購轉向享受關稅豁免的供應商，或重新設計產品以納入國內現有零件。雖然此類調整可能會降低長期風險，但也可能需要資本投資、供應鏈重組和服務合約重新談判，所有這些都可能帶來實施風險和短期成本波動。為了穩定單位成本，實驗室和醫院可以透過改變採購週期、整合採購以及簽訂長期服務和耗材合約來應對，這可能會有利於提供更廣泛服務和靈活條款的供應商。

關稅也會對分散式檢查部署的經濟效益產生重大影響。如果關鍵零件的關稅增加了可攜式和即時診斷設備的增量成本，部署決策可能會傾向於集中式、高通量模式，因為規模經濟可以部分抵消關稅的影響。相反，如果對專用試劑造成不成比例的影響，關稅可能會將需求轉向受進口影響較小的替代診斷方法，從而加速對國產檢測試劑和技術的投資，這些試劑和技術更多地依賴軟體和分析技術，而非高成本耗材。

此外，關稅帶來的不確定性也將影響臨床研發。進行需要進口診斷試劑套件的多中心臨床試驗的申辦者可能會面臨更高的檢測成本、更長的試劑套件分發和合規時間，這可能會影響場地選擇和伴隨診斷部署的時間表。最後，應從策略角度看待關稅的累積影響。在臨床實驗政策持續波動的環境下，那些投資於供應鏈透明度、採購多元化和自適應定價策略的組織將處於有利地位，能夠維持核心臨床和商業管道的服務水準和市場進入。

價值鏈主導的洞察映射技術特定的價值鏈、癌症類型診斷需求以及不同的最終用戶採用途徑，以實現策略優先排序

細緻的細分鏡頭揭示了每種技術平台、癌症類型和最終用戶管道的獨特機會和風險狀況，為產品定位和商業化提供了策略清晰度。在技​​術領域，流式細胞技術分為細胞分選和多參數流式細胞技術，每種技術都有不同的臨床和研究應用。細胞分選對於轉化研究和自體細胞治療至關重要，而多參數流式細胞技術推動血液學診斷和微量殘存疾病評估中的免疫表現型分析。影像技術包括 CT、MRI、正子斷層掃描和超音波，每種方式都為診斷、分期和治療監測提供獨特的價值。當代謝和功能資訊為標靶治療選擇提供資訊時，PET 和 MRI 尤其重要，而 CT 和超音波繼續在急性護理和門診環境中提供廣泛可及的快速成像終點。

免疫組織化學方法細分為顯色法和螢光法，反映了既定工作流程與更複雜的空間解析度之間的權衡。顯色法在常規病理學中仍然普遍應用，而螢光法則能夠實現多重生物標記組合和空間分析。原位雜合反應補充了微陣列、PCR和定序技術中的分子診斷，並且對於檢測組織結構內的基因重排和拷貝數變異仍然至關重要。在分子診斷領域，當需要進行廣泛的基因表現譜分析時，微陣列技術仍被廣泛使用；PCR技術憑藉其靈敏度和快速性，在標靶突變檢測和微小殘留疾病檢測中保持著核心作用；定序則提供了全面的基因組學見解，日益支持精準腫瘤學決策。

癌症類型的細分揭示了骨髓惡性腫瘤和固態腫瘤的不同診斷需求。血液系統惡性腫瘤，如白血病、淋巴瘤和多發性骨髓瘤，嚴重依賴流式細胞技術、分子檢測和以骨髓為中心的工作流程進行診斷、疾病分類和治療監測。固體癌，例如乳癌、結直腸癌、肺癌和前列腺癌，需要結合組織免疫組織化學、原位雜合反應和定序的整合流程，以指導生物標記主導的治療選擇。不同的癌症亞型對檢體處理、檢測靈敏度和生物標記檢驗有不同的要求，這些要求決定了商業策略。

終端用戶細分——門診、診斷實驗室、醫院和研究機構——影響採用速度和採購複雜性。門診優先考慮照護現場效率和快速報告，而診斷實驗室則強調吞吐量、認證合規性和每次檢測成本。醫院必須平衡其內部容量和轉診網路，並且通常傾向於整合供應商解決方案以及捆綁服務和培訓。包括學術和商業研究中心在內的研究機構推動新平台的早期採用，並在檢測檢驗和臨床效用研究中既是客戶又是合作者，提供關鍵的證據生成夥伴關係。總而言之，這些細分動態強調了需要根據每個終端使用者群體的臨床工作流程、報銷環境和營運限制制定差異化的價值提案。

全球不同的報銷制度、法律規範和醫療保健基礎設施將如何影響採用的優先事項和商業策略

美洲、歐洲、中東和非洲以及亞太地區的區域動態對技術採用、報銷途徑和夥伴關係模式有著重大影響，每個地區都代表著獨特的醫療保健結構和創新生態系統。這種環境支持高價值分子檢測和先進影像診斷技術的快速普及，但也需要強力的示範計畫來確保報銷和處方資格。此外，美洲的採購慣例通常傾向於簽訂綜合性的長期服務協議，青睞那些提供全面售後支援和耗材供應網路的供應商。

在歐洲、中東和非洲，報銷體系更加多樣化，在檢測報銷標準方面也往往更加嚴格，如果沒有強力的衛生經濟數據，這可能會減緩新診斷方法的推廣。歐洲的監管協調和跨國合作正在加強，而政府主導的三級醫療和診斷基礎設施投資正在推動中東和非洲的創新。在該地區營運的供應商應利用不同的國家報銷框架，優先考慮本地證據生成，並與認可的實驗室合作，以提高採用率。

亞太地區是一個快速擴張的商業機會區，其市場成熟度參差不齊，既有定序和數位病理學應用日益普及的已開發國家，也有重視照護現場診斷和經濟高效成像的新興市場。政府主導的強化癌症篩檢計畫和對國內製造能力的投資，正在塑造採購偏好和本地夥伴關係。清晰的監管途徑、在地化的技術支援和價格敏感度在亞太地區的打入市場策略中發揮著至關重要的作用。

綜上所述，這些區域差異需要差異化的商業性策略，以平衡全球平台一致性與區域​​特定證據產生、監管導航和客製化服務模式。與本地經銷商建立策略合作夥伴關係、進行有針對性的臨床合作以及製定靈活的定價策略，對於將產品功能轉化為跨不同醫療保健系統的永續臨床和商業性應用至關重要。

平台規模、偵測專業化、服務經濟性和策略聯盟所形成的競爭動態將決定商業性彈性和成長軌跡

診斷腫瘤學領域的競爭態勢由大型整合平台提供者、專業檢測試劑開發商以及專注於利基臨床應用的敏捷新參與企業所構成。現有的儀器製造商繼續利用其規模、廣泛的服務產品和整合的耗材生態系統來保護裝置量，而專業公司則透過檢測試劑創新、軟體支援的分析以及與臨床中心的策略夥伴關係關係來實現差異化。在整個競爭格局中，差異化越來越取決於能否證明臨床效用、透過自動化簡化檢測工作流程以及提供持久的服務和試劑供應。

夥伴關係與收購仍是產能擴張的核心。大型診斷公司經常進行補充性收購，例如提升定序能力、增加多重免疫檢測能力，或引入數位病理學和人工智慧解讀工具。同時，規模較小的開發人員通常會尋求與學術醫療中心和受託研究機構達成聯合開發協議，以加速臨床檢驗並產生參考資料集，以支援監管提交和付款人談判。儀器製造商和專業試劑供應商之間的策略共同開發契約也很常見，它們會協調產品藍圖，提供捆綁提案，從而簡化採購並確保試劑供應。

服務經濟性和耗材收益流對商業性可行性至關重要。將強大的現場服務網路與可預測的耗材收益模式結合的供應商，將受益於更高的終身客戶價值和更強的採購週期波動抵禦能力。軟體和資訊科技產品能夠實現跨模態資料整合、促進縱向病患追蹤並支持真實世界證據生成，從而進一步提升供應商的差異化優勢。投資於雲端對應平臺和可互通資料標準的公司，可以透過提供分析服務並簡化臨床實驗室和醫療系統的多模態診斷工作流程，從而釋放更高的價值。

整體而言，競爭格局將有利於那些將卓越的科學研究能力與強大的營運能力結合的機構。那些能夠快速檢驗臨床效用、確保試劑和服務的不間斷獲取、並提供可互通的診斷生態系統的機構，將最有可能抓住精準腫瘤學日益成長的需求。

加強供應彈性、證據產生和綜合臨床部署是診斷領導者為實現永續成長應優先採取的策略行動

產業領導者應採取一系列務實的優先行動，將新興趨勢轉化為永續的競爭優勢。這些措施包括評估替代供應商、評估區域和聯合生產機會，以及實施平衡營運成本和供應連續性的庫存策略。其次，制定實證藍圖，展示關鍵適應症的臨床效用和健康經濟價值。早期投資前瞻性研究和真實世界證據可以加速付款方參與，並促進報銷談判，尤其對於高成本的分子檢測和伴隨診斷。

第三，我們將優先考慮產品的互通性以及與臨床工作流程的整合，採用開放標準並與電子健康記錄和實驗室資訊系統供應商建立夥伴關係。透過簡化整合，我們將減少部署摩擦，並提高醫院和參考實驗室對診斷解決方案的採用率。第四，我們將根據當地實際情況定製商業模式。我們將實施彈性價格設定和合約簽訂方式，以適應不同的報銷環境和採購週期，並在執行時間和耗材獲取對客戶滿意度至關重要的地區投資服務能力。

第五，我們將與學術中心、臨床網路和研究機構建立策略夥伴關係，以加速驗證，產生可靠的資料集，並共同創建臨床路徑，將診斷技術整合到標準治療中。這些合作也將作為新興臨床需求和監管趨勢的早期檢測系統。最後，我們將採用模組化開發方法，縮短迭代周期，並使產品開發與不斷變化的付款人證據要求保持一致，從而增強研發和商業化流程的敏捷性。這些舉措將使我們能夠在風險規避與成長導向之間取得平衡，並在充滿活力的癌症診斷市場中負責任地實現規模擴張。

結合相關人員訪談、文獻綜合、定量映射和同行檢驗的強大混合方法研究框架確保了基於證據的發現

本執行綜合報告的基礎研究採用了混合方法，旨在整合來自多個互補資訊來源的見解，並透過專家諮詢檢驗研究結果。主要研究包括對醫院、診斷實驗室和研究機構的臨床負責人、實驗室主任和採購主管進行結構化訪談，以及對診斷製造機構和技術供應商的高階主管進行訪談。這些訪談提供了關於應用促進因素、採購限制和影響報銷決策的證據需求的定性背景資訊。

二次研究包括對同行評審的臨床文獻、監管指南文件、技術白皮書以及關於診斷技術、檢測性能特徵和臨床效用研究的公開資訊進行系統性綜述。在可獲得的情況下，評估了真實世界資料集和註冊分析，以了解診斷路徑的背景，並確定檢測方法的使用和臨床決策的模式。綜合這些資訊來源的研究結果，以確定趨同的主題，並交叉檢驗主要訪談中提出的斷言。

定量分析包括將產品系列與細分矩陣進行映射，評估關鍵成分的供應鏈集中度，以及情境分析，以評估關稅變化等政策變化的潛在影響。由病理學家、分子診斷科學家、放射科醫生和衛生經濟學專家組成的專家小組進行了壓力測試，以確認臨床相關性並完善建議。透過透明地記錄訪談方案、資訊來源和局限性，保持了調查方法的嚴謹性，使讀者能夠評估關鍵結論背後證據的強度。

綜合策略要點表明，臨床效用、供應鏈彈性和綜合解決方案將決定癌症診斷的長期成功

累積的生態系統分析表明，腫瘤診斷生態系統正處於一個戰略曲折點，技術潛力、付款人期望和供應鏈現實在此交匯。對於那些能夠將技術差異化轉化為可證明的臨床價值，同時確保在貿易和採購波動中保持營運韌性的組織來說，機會無限。多模態診斷和綜合彙報的趨勢將越來越青睞那些提供可互通解決方案並與臨床相關人員積極合作，將診斷技術整合到治療路徑中的供應商。

同時，嚴謹的證據生成和適應性強的商業模式將獲得回報。缺乏臨床效用和成本效益有力證明的測試和平台將在應用方面面臨阻力，尤其是在報銷框架保守的市場。此外，管理供應鏈複雜性（包括在地化、採購多元化和策略夥伴關係）的能力對於進入市場和維護客戶信心也至關重要。

總而言之，最有可能獲得長期價值的組織是那些將科學創新與務實部署策略相結合的組織：投資高品質的證據，建構有韌性的供應和服務網路，設計可互通且方便臨床醫生的解決方案，並減少實際實踐中的摩擦。這些優先事項是不斷發展的癌症診斷市場實現可擴展成長的基礎。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • 整合人工智慧演算法用於早期癌症檢測和風險分層
  • 採用液態生物檢體檢測，微創監測腫瘤動態和治療反應
  • 基於基因組分析數據擴展個人化腫瘤治療的伴隨診斷
  • 實施結合蛋白質體學和代謝體學的多體學方法進行全面的腫瘤分析
  • 分散式 POC 癌症篩檢平台的成長，使患者能夠遠端存取和早期療育
  • 監管部門的核准和報銷範圍的擴大加速了腫瘤診斷領域次世代定序的普及

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第8章癌症診斷市場（按技術）

  • 流式細胞技術
    • 細胞分選
    • 多參數流式細胞技術
  • 影像學
    • 電腦斷層掃描
    • 磁振造影
    • 正子斷層掃描
    • 超音波
  • 免疫組織化學
    • 顯色
    • 螢光
  • 原位雜合技術
  • 分子診斷
    • 微陣列
    • PCR
    • 定序

第9章 癌症診斷市場（按癌症類型）

  • 血癌
    • 白血病
    • 淋巴瘤
    • 多發性骨髓瘤
  • 固態腫瘤
    • 乳癌
    • 大腸直腸癌
    • 肺癌
    • 攝護腺癌

第 10 章癌症診斷市場（按最終用戶）

  • 門診治療
  • 診斷實驗室
  • 醫院
  • 研究所
    • 學術機構
    • 私人研究中心

第11章癌症診斷市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 癌症診斷市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 癌症診斷市場（按國家）

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • F. Hoffmann-La Roche Ltd
    • Abbott Laboratories
    • Thermo Fisher Scientific Inc.
    • Danaher Corporation
    • QIAGEN NV
    • Sysmex Corporation
    • Illumina, Inc.
    • bioMerieux SA
    • Siemens Healthineers AG
    • Agilent Technologies, Inc.
Product Code: MRR-436145BF8B0C

The Cancer Diagnostics Market is projected to grow by USD 83.23 billion at a CAGR of 12.12% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 33.31 billion
Estimated Year [2025] USD 37.32 billion
Forecast Year [2032] USD 83.23 billion
CAGR (%) 12.12%

An urgent and comprehensive orientation to the evolving oncology diagnostics environment driven by technology convergence, care pathway transformation, and regulatory shifts

The oncology diagnostics landscape is experiencing a period of rapid evolution driven by technological convergence, regulatory recalibration, and shifting clinical pathways. Advances across molecular platforms, high-resolution imaging, and sophisticated cellular analytics are expanding the capabilities of clinicians and researchers to detect, subtype, and monitor cancer with unprecedented precision. At the same time, care delivery models are changing as diagnostic decision-making migrates closer to the patient, and as multidisciplinary teams demand integrated information flows that combine histopathology, genomic sequencing, and imaging-derived biomarkers.

Against this backdrop, market participants face a complex interplay of innovation opportunities and operational challenges. Diagnostic developers are competing on assay sensitivity and specificity, throughput, and cost of ownership, while health systems increasingly emphasize value-based outcomes and diagnostic efficiency. Regulatory expectations for companion diagnostics and next-generation sequencing workflows are maturing, and payers are reassessing reimbursement pathways for tests that promise improved treatment selection and reduced downstream costs. As a result, the competitive environment rewards organizations that can pair scientific rigor with pragmatic deployment strategies that address clinical workflows and reimbursement realities.

This executive summary synthesizes the most consequential trends reshaping cancer diagnostics, analyzes potential policy and tariff-driven disruptions, delineates segmentation-level insights across technology, cancer type, and end user, evaluates regional dynamics, and identifies strategic options for companies seeking to sharpen their competitive positioning. The subsequent sections provide a cohesive narrative designed to inform corporate strategy, investment decisions, and operational planning across stakeholder groups involved in oncology diagnostics and associated services.

How technological democratization, multimodal data integration, and regulatory realignment are jointly redefining diagnostic pathways and commercial imperatives in oncology

The diagnostic oncology landscape is being transformed by a set of interrelated shifts that together are redefining clinical practice and commercial opportunity. Technological democratization is a central theme: platforms once confined to specialized reference laboratories are moving into routine hospital laboratories and ambulatory settings as assay workflows are simplified, automation increases, and digital interfaces standardize results interpretation. This diffusion is accelerating the adoption of molecular diagnostics and advanced immunoassays in community settings, enabling earlier detection and more granular disease stratification.

Simultaneously, the integration of multimodal data streams is reshaping diagnostic outputs. Clinicians now expect reports that combine genomic findings with immunohistochemical patterns, spatial profiling, and cross-sectional imaging biomarkers, creating more actionable diagnostic narratives for precision therapy selection and longitudinal monitoring. This shift incentivizes cross-disciplinary collaboration between pathology, radiology, and molecular diagnostic teams, and it favors companies that can offer interoperable systems or curated data platforms that reduce friction in data synthesis.

Payer and regulatory environments are also influencing strategic direction. Payers are increasingly focused on demonstrable clinical utility and real-world outcomes, prompting diagnostic developers to invest in evidence-generation programs and outcomes studies. Regulators are adapting frameworks to address novel test modalities, companion diagnostics, and decentralized testing, which is accelerating the need for robust analytical validation and post-market surveillance. Finally, supply chain resilience and cost pressures are prompting manufacturing realignment and more selective procurement practices, encouraging vertical integration and strategic alliances focused on securing critical reagent supplies and instrument service networks.

Taken together, these transformative shifts create a landscape where technological innovation alone is insufficient; success requires interoperable solutions, evidence-driven adoption strategies, and operational resilience that collectively enable diagnostics to be both clinically impactful and commercially sustainable.

Assessing the multi-dimensional consequences of 2025 U.S. tariff measures on supply chains, procurement costs, and strategic deployment of diagnostic technologies

Tariff changes announced or implemented in 2025 in the United States present a complex set of upstream and downstream implications for companies operating in the diagnostic oncology space. At the most direct level, increased duties on imported instruments and reagents can raise landed costs for high-capital equipment such as imaging modalities, flow cytometers, and sequencers, as well as for specialized consumables that lack mature domestic manufacturing alternatives. These cost pressures can compress margins for manufacturers that rely on global supply chains and can increase acquisition and per-test costs for laboratories and health systems that import equipment or rely on foreign-produced reagents.

Beyond direct pricing effects, tariffs can precipitate strategic responses across the value chain. Manufacturers may accelerate regionalization of production, shift sourcing to tariff-exempt suppliers, or redesign products to incorporate components that are domestically available. Such adjustments can reduce exposure over time but may require capital investment, requalification of supply chains, and renegotiation of service contracts, each of which can introduce implementation risk and near-term cost volatility. Laboratories and hospitals may respond by modifying procurement cycles, consolidating purchasing, or entering into longer-term service and consumable agreements to stabilize unit costs, which could favor vendors with broad service footprints and flexible commercial terms.

Tariffs also materially affect the economics of decentralized testing adoption. If the incremental cost of portable or point-of-care devices rises due to duties on critical components, deployment decisions may favor centralized high-throughput models where economies of scale can partially neutralize tariff impacts. Conversely, tariffs that disproportionately affect specialized reagents could shift demand toward alternative diagnostic modalities with lower import exposure, potentially accelerating investment in domestically manufactured assays or in technologies that rely more on software and analytics than on high-cost consumables.

In addition, tariff-induced uncertainty has implications for clinical research and development. Sponsors conducting multi-site trials that require imported diagnostic kits may face higher trial costs and longer timelines for kit distribution and regulatory compliance. This could influence site selection and the timing of companion diagnostic rollouts. Finally, the cumulative impact of tariffs should be viewed through a strategic lens: in environments of sustained trade policy volatility, organizations that invest in supply chain transparency, diversified sourcing, and adaptive pricing strategies will be better positioned to maintain service levels and preserve market access in core clinical and commercial channels.

Deep segmentation-driven insights that map technology-specific value chains, cancer-type diagnostic needs, and varied end-user adoption pathways for strategic prioritization

A granular segmentation lens reveals differentiated opportunity and risk profiles across technological platforms, cancer types, and end-user channels, offering strategic clarity for product positioning and commercialization. Within technology, flow cytometry splits into cell sorting and multiparameter flow cytometry segments, each with distinct clinical and research applications; cell sorting remains essential for translational research and autologous cell therapies, while multiparameter flow cytometry drives immunophenotyping in hematological diagnostics and minimal residual disease assessment. Imaging technologies encompass computed tomography, magnetic resonance imaging, positron emission tomography, and ultrasound, with each modality contributing unique value to diagnosis, staging, and treatment monitoring; PET and MRI are particularly pivotal where metabolic and functional readouts inform targeted therapy selection, whereas CT and ultrasound continue to offer broad accessibility and rapid imaging endpoints in acute care and outpatient pathways.

Immunohistochemistry subdivisions between chromogenic and fluorescent approaches reflect a trade-off between established workflows and higher-plex spatial resolution, with chromogenic methods maintaining ubiquity in routine pathology while fluorescent assays enable multiplexed biomarker panels and spatial profiling. In situ hybridization remains critical for detecting gene rearrangements and copy number changes within tissue architecture, complementing molecular diagnostics that span microarray, PCR, and sequencing technologies. Within molecular diagnostics, microarray applications persist where broad gene expression profiling is needed, PCR maintains a central role for targeted mutation detection and minimal residual disease assays due to its sensitivity and turnaround speed, and sequencing delivers comprehensive genomic insights that increasingly underpin precision oncology decisions.

Cancer-type segmentation highlights divergent diagnostic needs between hematological malignancies and solid tumors. Hematological cancers, including leukemia, lymphoma, and multiple myeloma, rely heavily on flow cytometry, molecular assays, and bone marrow-focused workflows for diagnosis, disease classification, and therapy monitoring. Solid tumors, comprising breast, colorectal, lung, and prostate cancers among others, demand integrated pipelines that combine tissue-based immunohistochemistry, in situ hybridization, and sequencing to inform biomarker-driven treatment selection. Each cancer subtype presents unique specimen handling, assay sensitivity, and biomarker validation requirements that shape commercial strategies.

End-user segmentation across ambulatory care, diagnostic laboratories, hospitals, and research institutes influences adoption velocity and procurement complexity. Ambulatory settings prioritize point-of-care efficiency and rapid reporting, whereas diagnostic laboratories emphasize throughput, accreditation compliance, and cost per test. Hospitals must balance in-house capacity with referral networks, often favoring integrated vendor solutions with service and training bundles. Research institutes, including academic centers and private research centers, drive early adoption of novel platforms and provide critical evidence-generation partnerships, acting as both customers and collaborators in assay validation and clinical utility studies. Collectively, these segmentation dynamics underscore the need for differentiated value propositions tailored to clinical workflows, reimbursement environments, and the operational constraints of each end-user cohort.

How divergent reimbursement regimes, regulatory frameworks, and healthcare infrastructures across global regions shape adoption priorities and commercial strategies

Regional dynamics exert a strong influence on technology adoption, reimbursement pathways, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific, each exhibiting distinct healthcare structures and innovation ecosystems. In the Americas, mature private and public payers coexist with leading academic centers and a robust commercial diagnostics sector; this environment supports rapid uptake of high-value molecular tests and advanced imaging but also demands strong evidentiary programs to secure reimbursement and formulary positioning. Furthermore, procurement practices in the Americas often favor integrated service arrangements and long-term service contracts, which can advantage vendors that offer comprehensive post-sales support and consumable supply networks.

In Europe, Middle East & Africa, reimbursement systems are more heterogeneous and often more prescriptive about test reimbursement criteria, which can slow adoption of novel diagnostics without strong health economic data. Regulatory harmonization efforts in Europe promote cross-border collaboration, while pockets of innovation in the Middle East and Africa are driven by government-led investments in tertiary care and diagnostic infrastructure. Vendors operating in this region must navigate diverse national reimbursement frameworks and prioritize local evidence generation and partnerships with accredited laboratories to scale adoption.

Asia-Pacific presents a rapidly expanding opportunity space characterized by varied maturity across markets, from advanced economies with high adoption of sequencing and digital pathology to emerging markets where point-of-care diagnostics and cost-effective imaging are paramount. Government-led initiatives to strengthen cancer screening programs and investments in domestic manufacturing capacity are shaping procurement preferences and local partnerships. Across Asia-Pacific, considerations such as regulatory pathway clarity, localization of technical support, and pricing sensitivity play decisive roles in go-to-market strategies.

Taken together, these regional distinctions call for differentiated commercial playbooks that balance global platform consistency with localized evidence generation, regulatory navigation, and tailored service models. Strategic alliances with regional distributors, targeted clinical partnerships, and adaptive pricing strategies will be instrumental in translating product capabilities into sustainable clinical and commercial uptake across diverse health systems.

Competitive dynamics shaped by platform scale, assay specialization, service economics, and strategic alliances that together determine commercial resilience and growth trajectories

Competitive dynamics in diagnostic oncology are defined by a mix of large integrated platform providers, specialized assay developers, and agile newcomers focused on niche clinical applications. Established instrument manufacturers continue to leverage scale, broad service footprints, and integrated consumable ecosystems to defend installed bases, while specialist companies differentiate through assay innovation, software-enabled analytics, and strategic partnerships with clinical centers. Across the competitive landscape, differentiation increasingly hinges on the ability to demonstrate clinical utility, streamline laboratory workflows through automation, and provide durable service and reagent supply arrangements.

Partnerships and acquisitions remain central to capability expansion. Larger diagnostic firms frequently pursue bolt-on acquisitions to augment sequencing capacity, add multiplexed immunoassay capabilities, or incorporate digital pathology and AI-enabled interpretation tools. Meanwhile, smaller developers often seek co-development agreements with academic medical centers and contract research organizations to accelerate clinical validation and create reference datasets that support regulatory submissions and payer discussions. Strategic collaborations between instrument manufacturers and specialty reagent providers are also common, aligning product roadmaps to create bundled propositions that simplify procurement and ensure reagent availability.

Service economics and consumables revenue streams play a critical role in commercial viability. Vendors that combine robust field service networks with predictable consumable revenue models benefit from higher lifetime customer value and greater resilience against procurement cycle volatility. Software and informatics offerings further differentiate vendors by enabling data integration across modalities, facilitating longitudinal patient tracking, and supporting real-world evidence generation. Companies that invest in cloud-enabled platforms and interoperable data standards can unlock higher value by offering analytics-as-a-service and by simplifying multi-modal diagnostic workflows for clinical laboratories and health systems.

Overall, the competitive environment rewards organizations that combine scientific excellence with operational execution: those that can rapidly validate clinical utility, ensure uninterrupted reagent and service availability, and deliver interoperable diagnostic ecosystems will be best positioned to capture growing demand in precision oncology.

Prioritized strategic actions for diagnostics leaders to strengthen supply resilience, evidence-generation, and integrated clinical deployment for sustainable growth

Industry leaders should pursue a set of pragmatic, prioritized actions to convert emerging trends into durable competitive advantage. First, invest in supply chain transparency and diversification to reduce exposure to tariff- or trade-driven disruptions; this includes assessing alternative suppliers, evaluating regional manufacturing or co-manufacturing opportunities, and implementing inventory strategies that balance working capital with continuity of supply. Second, develop evidence-generation roadmaps that demonstrate clinical utility and health-economic value across key indications; early investment in prospective studies and real-world evidence will accelerate payer engagement and facilitate reimbursement discussions, particularly for high-cost molecular tests and companion diagnostics.

Third, prioritize product interoperability and integration with clinical workflows by adopting open standards and building partnerships with electronic health record and laboratory information system vendors. Simplifying integration reduces adoption friction in hospitals and reference laboratories and increases the stickiness of diagnostic solutions. Fourth, tailor commercial models to regional realities; deploy flexible pricing and contracting approaches that account for differing reimbursement environments and procurement cycles, and invest in regional service capabilities where uptime and consumable access are central to customer satisfaction.

Fifth, cultivate strategic partnerships with academic centers, clinical networks, and research institutes to accelerate validation, generate robust datasets, and co-create clinical pathways that embed diagnostics into standard care. These collaborations can also serve as early-warning systems for emerging clinical needs and regulatory trends. Finally, embed agility into R&D and commercialization processes by adopting modular development approaches, shortening iteration cycles, and aligning product development with evolving payer evidence requirements. Together, these actions balance risk mitigation with growth orientation and position organizations to scale responsibly in a dynamic oncology diagnostics market.

A robust mixed-methods research framework combining stakeholder interviews, literature synthesis, quantitative mapping, and expert validation to ensure evidence-based findings

The research underpinning this executive synthesis employed a mixed-methods approach designed to triangulate insights from multiple, complementary sources and to validate findings through expert consultation. Primary research included structured interviews with clinical leaders, laboratory directors, and procurement executives across hospitals, diagnostic laboratories, and research institutes, supplemented by interviews with senior executives from diagnostic manufacturing organizations and technology vendors. These engagements provided qualitative context on adoption drivers, procurement constraints, and the evidence needs that influence reimbursement decisions.

Secondary research encompassed a systematic review of peer-reviewed clinical literature, regulatory guidance documents, technical white papers, and public disclosures relating to diagnostic technologies, assay performance characteristics, and clinical utility studies. Where available, real-world datasets and registry analyses were assessed to contextualize diagnostic pathways and to identify patterns in assay utilization and clinical decision-making. Insights from these sources were synthesized to identify convergent themes and to cross-validate claims made in primary interviews.

Quantitative analyses included mapping of product portfolios against segmentation matrices, assessment of supply chain concentration for critical components, and scenario analysis to evaluate potential impacts of policy shifts such as tariff changes. Findings were stress-tested via expert panels comprising pathologists, molecular diagnostic scientists, radiologists, and health economics specialists to ensure clinical plausibility and to refine recommendations. Throughout the process, methodological rigor was maintained through transparent documentation of interview protocols, source attribution, and limitations, enabling readers to assess the strength of evidence behind key conclusions.

Synthesis of strategic imperatives showing that clinical utility, supply chain resilience, and integrated solutions determine long-term success in oncology diagnostics

The cumulative analysis points to a diagnostic oncology ecosystem at a strategic inflection point where technological potential, payer expectations, and supply chain realities intersect. Opportunities abound for organizations that can translate technological differentiation into demonstrable clinical value while ensuring operational resilience in the face of trade and procurement volatility. The trend toward multimodal diagnostics and integrated reporting will increasingly favor vendors that provide interoperable solutions and active collaboration with clinical stakeholders to embed diagnostics into care pathways.

At the same time, the landscape will reward disciplined evidence generation and adaptive commercial models. Tests and platforms that lack robust demonstration of clinical utility and cost-effectiveness will face adoption headwinds, particularly in markets with conservative reimbursement frameworks. Additionally, the capacity to manage supply chain complexity, whether through localization, diversified sourcing, or strategic partnerships, will be a deciding factor in sustaining market access and customer trust.

In sum, the organizations most likely to capture long-term value are those that align scientific innovation with pragmatic deployment strategies: they will invest in high-quality evidence, build resilient supply and service networks, and design interoperable, clinician-friendly solutions that reduce friction in real-world practice. These priorities will serve as the foundation for scalable growth in the evolving oncology diagnostics marketplace.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Integration of artificial intelligence algorithms for early cancer detection and risk stratification
  • 5.2. Adoption of liquid biopsy tests for minimally invasive monitoring of tumor dynamics and treatment response
  • 5.3. Expansion of companion diagnostics for personalized oncology therapies driven by genomic profiling data
  • 5.4. Implementation of multiomics approaches combining proteomics and metabolomics for comprehensive tumor profiling
  • 5.5. Growth of decentralized point-of-care cancer screening platforms enabling remote patient access and early intervention
  • 5.6. Regulatory approvals and reimbursement expansions accelerating access to next-generation sequencing in oncology diagnostics

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cancer Diagnostics Market, by Technology

  • 8.1. Flow Cytometry
    • 8.1.1. Cell Sorting
    • 8.1.2. Multiparameter Flow Cytometry
  • 8.2. Imaging
    • 8.2.1. Computed Tomography
    • 8.2.2. Magnetic Resonance Imaging
    • 8.2.3. Positron Emission Tomography
    • 8.2.4. Ultrasound
  • 8.3. Immunohistochemistry
    • 8.3.1. Chromogenic
    • 8.3.2. Fluorescent
  • 8.4. In Situ Hybridization
  • 8.5. Molecular Diagnostics
    • 8.5.1. Microarray
    • 8.5.2. Pcr
    • 8.5.3. Sequencing

9. Cancer Diagnostics Market, by Cancer Type

  • 9.1. Hematological Cancers
    • 9.1.1. Leukemia
    • 9.1.2. Lymphoma
    • 9.1.3. Multiple Myeloma
  • 9.2. Solid Tumors
    • 9.2.1. Breast Cancer
    • 9.2.2. Colorectal Cancer
    • 9.2.3. Lung Cancer
    • 9.2.4. Prostate Cancer

10. Cancer Diagnostics Market, by End User

  • 10.1. Ambulatory Care
  • 10.2. Diagnostic Laboratories
  • 10.3. Hospitals
  • 10.4. Research Institutes
    • 10.4.1. Academic Institutes
    • 10.4.2. Private Research Centers

11. Cancer Diagnostics Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Cancer Diagnostics Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Cancer Diagnostics Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Analysis
    • 14.3.1. F. Hoffmann-La Roche Ltd
    • 14.3.2. Abbott Laboratories
    • 14.3.3. Thermo Fisher Scientific Inc.
    • 14.3.4. Danaher Corporation
    • 14.3.5. QIAGEN N.V.
    • 14.3.6. Sysmex Corporation
    • 14.3.7. Illumina, Inc.
    • 14.3.8. bioMerieux SA
    • 14.3.9. Siemens Healthineers AG
    • 14.3.10. Agilent Technologies, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. MIDDLE EAST CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASEAN CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GCC CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. EUROPEAN UNION CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. BRICS CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. G7 CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. NATO CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. CANCER DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 26. CANCER DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CANCER DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CELL SORTING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPARAMETER FLOW CYTOMETRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COMPUTED TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY POSITRON EMISSION TOMOGRAPHY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ULTRASOUND, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CHROMOGENIC, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY FLUORESCENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY IN SITU HYBRIDIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MICROARRAY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SEQUENCING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY MULTIPLE MYELOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY COLORECTAL CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY LUNG CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PROSTATE CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY AMBULATORY CARE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY ACADEMIC INSTITUTES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY PRIVATE RESEARCH CENTERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CANCER DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 213. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 214. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 215. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 218. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 219. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 220. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 221. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 222. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 223. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 224. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 225. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 226. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 227. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 228. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 229. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 230. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 231. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 232. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 233. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 234. AMERICAS CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 235. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 239. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 240. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 241. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 242. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 243. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 244. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 245. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 246. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 247. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 250. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 251. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 252. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 253. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 254. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 255. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 256. NORTH AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 257. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 258. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 259. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 260. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 261. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 262. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 263. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 264. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 265. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 266. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 267. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 268. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 269. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 270. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 271. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 272. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 273. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 274. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 275. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 276. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 277. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 278. LATIN AMERICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 279. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 280. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 281. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 282. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 283. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 284. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 285. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 286. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 287. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2025-2032 (USD MILLION)
  • TABLE 301. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2032 (USD MILLION)
  • TABLE 305. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2018-2024 (USD MILLION)
  • TABLE 306. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY FLOW CYTOMETRY, 2025-2032 (USD MILLION)
  • TABLE 307. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2018-2024 (USD MILLION)
  • TABLE 308. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMAGING, 2025-2032 (USD MILLION)
  • TABLE 309. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2018-2024 (USD MILLION)
  • TABLE 310. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY IMMUNOHISTOCHEMISTRY, 2025-2032 (USD MILLION)
  • TABLE 311. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2024 (USD MILLION)
  • TABLE 312. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2025-2032 (USD MILLION)
  • TABLE 313. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY CANCER TYPE, 2025-2032 (USD MILLION)
  • TABLE 315. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2018-2024 (USD MILLION)
  • TABLE 316. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL CANCERS, 2025-2032 (USD MILLION)
  • TABLE 317. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2018-2024 (USD MILLION)
  • TABLE 318. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY SOLID TUMORS, 2025-2032 (USD MILLION)
  • TABLE 319. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 320. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 321. EUROPE CANCER DIAGNOSTICS MARKET SIZE, BY RESEARCH INSTITUTES, 2018-2024 (USD MILLION)

TAB